Antibodies: Volume 2: Novel Technologies and Therapeutic Use PDF
Preview Antibodies: Volume 2: Novel Technologies and Therapeutic Use
ANTIBODIES VOLUME 2: NOVEL TECHNOLOGIES AND THERAPEUTIC USE ANTIBODIES VOLUME 2: NOVEL TECHNOLOGIES AND THERAPEUTIC USE Edited by G. Subramanian Linleboume, Kent, United Kingdom Springer Science+Business Media, LLC Library ofCongress Cataloging-in-Publication Data Antibodies 1 edited by G. Subramanian. p. ;cm. Includes bibliographical references and index. Contents: v. I. Production and purification --v. 2. Novel technologies and therapeutic use. (divisible set) I. Monoclonal antibodies--Synthesis. 2. Monoclonal antibodies--Therapeutic use. 3. Monoclonal antibodies--Biotechnology. I. Subramanian, G., 1935- [DNLM: I. Antibodies, Monoclonal--isolation & purification. 2. Antibodies, Monoclonal--therapeutic use. 3. Biotechnology--methods. 4. Chrornatography--methods. QW 575.5.A6 A6283 2004] TP248.65.M65A55 2004 615'.37--dc22 2003069160 ISBN 978-1-4613-4702-6 ISBN 978-1-4419-8877-5 (eBook) DOI 10.1007/978-1-4419-8877-5 ©2004 Springer Science+Business Media New York Originally published by Kluwer Academic Publishers/Plenum Publishers, New York in 2004 Softcover reprint of the hardcover I SI edition http://www.wkap.nl/ \0987654321 A C.I.P. record for this book is available from the Library of Congress All rights reserved No part of this book may be reproduced, stored in a retrieval system, or transmilled in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without wrinen permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work .. Permissions for books published in Europe: permissions@w/uJp.nl Permissions for books published in the United States of America: pennissions@w/uJp.com Preface It is now over one hundred years since von Behring and Kitsato first concluded experiments that led to the use of passive immunisation, employing antibodiesraisedinanimalsagainst tetanusanddiphtheriatoxins. The advancement oftechnology both in manufacturing purity product in a cost effective way and the clinical research has proved that antibodies are oneofthemostsuccessfulproductsinbiotechnology. Monoclonal antibodies account forbetween one-third andone-halfofall pharmaceutical products in development and human clinical trials. Both the nature ofmonoclonal antibody therapies and the relatively large size ofthe monoclonal antibody dictate theproduction requirements, formanyofthese therapeutics the monoclonal antibody product will be 100 kilogrammes or more per year.It iswidelyacknowledged that thereiscurrentlyaworldwide shortage of biomanufacturing capacity, and the active pharmaceutical ingredient materialrequirements for theseproducts are expectedtoincrease. Thustheindustry islooking fornew sourcesand extensivestudiesarebeing carried out not only foralternative technology to meet the needsbut also to revealthenewtherapeuticapplicationsofantibodies. This book brings to the forefront current advances in novel technologies for the manufacturing of monoclonal antibodies and also their extensive clinical importance. The first four chapters give an overview of the new technologies and the successful application in the manufacture of monoclonal antibodies with clinical purity. The next chapters address the application ofantibodies in cancer therapy and functional genomictherapy. The last chapter projects the importance ofantibodies and the prospects of antibody engineeringandtherapyforthefuture. v vi Preface It is my hope that this book will bring together accumulated knowledge in a way which will promote the advancement ofthe antibody field, which will continue to grow and develop new antibodies that are useful to society atlarge. I gratefully acknowledge the authors for their time and motivation in preparing their contributions, without which this book would not have been possible. Ishouldbe mostgrateful for anysuggestions, which couldserveto improve future editionsofthisbook Finally I would like to thank Jo Lawrence ofKluwer Academic/Plenum forherkeeninterestandhelpthroughout thecompletion ofthisbook. G. Subramanian Contributors Jean-PierreAbastado ImmunoDesignedMolecule(10M) 172rue deCharonne 75011 Paris Cedex 11 France Adrian AufDer Maur ESBATechAG Wagistrasse21 8952 ZUrich-Schlieren Switzerland FabriceAuzelle ImmunoDesignedMolecule(10M) 172rue deCharonne 75011 Paris Cedex 11 France DavidAzira DepartmentofRadiationOncology CRLCVal d'Aurelle-PaulLamarque F-34298MontpellierCedex5 France Alcide Barberis ESBATechAG Wagistrasse21 8952 ZUrich-Schlieren Switzerland vii V111 Contributors Jacques Bartholeyns ImmunoDesignedMolecule(IDM) 172ruedeCharonne 75011ParisCedex II France EmmanuelleBonnin INSERMU255 CentredeRecherchesBiomedicalesdesCordeliers IS,ruedel'EcoledeMedicine 75270ParisCedex06 France Egisto Boschetti CiphergenBiosystems-Biosepra 48,AvenuedesGenottes F-95800,Cergy France AurtHieBoyer ImmunoDesignedMolecule(IDM) 172ruedeCharonne 75011ParisCedex II France Manuela Campiglio MolecularTargetingUnit DepartmentofExperimentalOncology IsitutoNazionaleTumori Milan Italy GabrielleCaravelho INSERMU542 Paris-SudUniversity 101ruedeTolbiac 7654ParisCedex13 France Alain Chapel InstituteofRadioprotectionandNuclearSafety IRSN/DAHD/SARAM Fontenay-aux-Roses France Contributors ix OlivierDeas INSERMU542 Paris-SudUniversity 101ruedeTolbiac 75654 ParisCedex 13 France X. K.Deng Meridian Bioscience 3471 River HillsDrive Cincinnati OH45244 USA DimiterS.Dimitrov LaboratoryofExperimentalandComputationalBiology Center forCancer Research NCI-Frederick,NIH Bldg 469, Room 246 P.O. Box B,MillerDrive Frederick MD 21702-1201 USA Jean-BernardDubois DepartmentofRadiationOncology CRLC Val d'Aurelle-PaulLamarque F-34298 MontpellierCedex 5 France AntoineDiirrbach INSERMU542 Paris-SudUniversity Rue deTolbiac 75654 ParisCedex 13 France Christian Frisch MorphoSysAG Lena-Christ-Strasse48 D-82152Martinsried/P1anegg Germany x Contributors FrancoisHirsch INSERMU542 Paris-SudUniversity 101 ruedeTolbiac 75654ParisCedex13 France SylvieJacod ImmunoDesignedMolecule(10M) 172ruedeCharonne 75011ParisCedex11 France ChristelLarbouret ImmunociblagodesTumeursetIngenieriedesAnticorps EMI-0227INSERM,UniversiteMontpellier1 CRLCVald'Aurelle-PaulLamarque F-34298MontpellierCedex5 France PeterLichtlen ESBATechAG Wagistrasse21 8952ZUrich-Schlieren Switzerland Delphine Loirat ImmunoDesignedMolecule(10M) 172ruedeCharonne 75011ParisCedex11 France AndresMcAllister ImmunoDesignedMolecule(10M) 172ruedeCharonne 75011ParisCedex11 France SylvieMenard MolecularTargetingUnit DepartmentofExperimentalOncology IsitutoNazionaleTumori Milan Italy Contributors Xl K. JohnMorrowJr. MeridianBioscience 3471 RiverHillsDrive Cincinnati OH45244 USA MaximeMoulard BioCytex 140Chemindel'Annee d'Afrique 13010Marseille France RalfOstendorp MorphoSysAG Lena-Christ-Strasse48 D-82152Martinsried/Planegg Germany MahmutOzashin DepartmentofRadiationOncology CentreHospitalierUniversitaireVaudois CH 1011 Lausanne Switzerland AndrePelegrtn ImmunociblagodesTumeursetIngenieriedesAnticorps EMI-0227INSERM, UniversiteMontpellier1 CRLCVald'Aurelle-PaulLamarque F-34298MontpellierCedex5 France SereneUaM. Pupa MolecularTargetingUnit DepartmentofExperimentalOncology IsitutoNazionaleTumori Milan Italy DidierPrigent ImmunoDesignedMolecule(10M) 172ruedeCharonne 75011 ParisCedex11 France
Description:The list of books you might like
